Gracell Biotechnologies Inc. (GRCL) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Gracell Biotechnologies Inc. (US:GRCL), currently being evaluated. In 2021, Gracell Biotechnologies Inc. generated $366,000 in revenue and -$361.29 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Gracell Biotechnologies Inc. is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2021): $366,000
- Free Cash Flow (2021): -$361.29 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.